Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Physical Medicine and Rehabilitation

Long-Term Monitoring: Life During and After Steroid Treatment

At a Glance

Long-term care for glucocorticoid-induced osteoporosis combines scheduled bone-density scans, fracture assessment, medication reviews, safe activity, and emotional support. Fracture risk often declines after steroids stop, but residual risk means medication changes need a clinician’s plan.

Managing Glucocorticoid-Induced Osteoporosis (GIOP) is a marathon, not a sprint. Because steroids can impact your bones for as long as you take them—and for some time after you stop—living well after a GIOP diagnosis means moving from the initial assessment into a steady routine of monitoring and self-care [1].

The goal of long-term care is to maintain your independence and mobility while minimizing the fear that can come with a chronic fracture risk.

Your Long-Term Surveillance Schedule

Regular check-ups are the only way to ensure your treatment is working. While your doctor will tailor a plan to your specific risk level, standard guidelines generally suggest the following [2][1]:

  • Bone Density (DXA) Scans: Most patients on continued steroids should have a DXA scan repeated at individualized 1- to 2-year intervals [2]. Scanning on the same machine helps detect real differences.
  • Vertebral Fracture Assessment (VFA): The modality and timing of spinal imaging (VFA or X-rays) may change after a fracture, a major dose change, or treatment initiation. They are not automatically required at every DXA visit, but repeat imaging depends on your risk and symptoms [1][3].
  • Clinical Assessments: You should have a clinical fracture assessment—including a height measurement, review of new back pain, and routine safety monitoring for your medication—at least once a year [2].

Understanding Bone Turnover Markers (BTMs)

Your doctor may selectively order blood tests called Bone Turnover Markers (such as P1NP or CTX) [4].

  • What They Show: These tests measure the “speed” at which your bone is being built or broken down [5][6].
  • How They are Used: They are not standard diagnostic tests for every patient and cannot by themselves confirm medication absorption. However, they can be interpreted in clinical context to help evaluate your response to therapy [4][6].
  • Timing Matters: For these tests to be accurate, they should be taken under standardized conditions (usually in the morning while fasting). Do not use these results to change your treatment independently [7][6].

Navigating ‘Scan Anxiety’ and Fear of Fracture

Living with the knowledge that your bones are fragile can take an emotional toll. Many patients experience “scan anxiety”—distress leading up to a DXA appointment—or a persistent fear of falling [8][9].

It is important to remember that the risk assessment is a tool for empowerment, not a prophecy. Knowing your risk allows you to take concrete actions—like fall-proofing your home or starting an indicated bone medication—that significantly lower your chances of an injury [2][10]. If fear of movement is preventing you from exercising or seeing friends, consider asking for a referral to a physical therapist specializing in safe balance training and bone health [8].

Life After Steroids: Does Bone Heal?

If you successfully taper off steroids completely, your bone health enters a new phase.

  • The Good News: Once the steroids stop, your fracture risk often begins to decline, and your bone density may stabilize or show some recovery [11][12].
  • The Residual Risk: However, your risk does not instantly return to “zero.” Prior fractures, age, ongoing disease, and falls still influence your overall risk [13][14].
  • Stopping Bone Meds: Do not stop your osteoporosis medication without a clinician’s plan just because you stopped your steroids. Your doctor will reassess your fracture risk. While a bisphosphonate might be placed on a holiday, denosumab requires a planned transition [2][15].

Maintaining Quality of Life

Long-term care is about more than just numbers on a scan; it is about how you feel and move.

  • Pain Management: If you have had a fracture, you may deal with persistent “mechanical” back pain even after the bone has healed [16]. Working with a specialist in physical medicine or pain management can help you stay active [16].
  • Safe Activity: Focus on activities that build “functional strength”—the kind of muscle that helps you catch your balance if you trip [17].

By staying consistent with your monitoring and being honest with your team about both your physical and emotional challenges, you can successfully manage the long-term impact of GIOP.

Common questions in this guide

How often do I need a bone-density scan while taking steroids?
For many people who continue steroid treatment, a DXA scan is repeated about every 1 to 2 years, but the timing is individualized. Using the same scanner can make changes easier to compare. Your clinician may adjust the schedule based on your fracture risk and treatment changes.
Do I need spine imaging every time I have a DXA scan?
Not necessarily. Spinal imaging is usually repeated when symptoms, a new fracture, a major steroid-dose change, treatment initiation, or overall risk makes it useful. Your clinician will choose between a vertebral fracture assessment and X-rays.
What can P1NP and CTX blood tests tell me about my osteoporosis treatment?
P1NP and CTX estimate how quickly bone is being built or broken down. They are used selectively, not as routine tests for everyone, and cannot by themselves prove that a medicine is being absorbed or is working. Results should be collected under the requested conditions, often while fasting in the morning, and interpreted by your clinician; do not change treatment based on them alone.
Will my fracture risk go away after I stop taking steroids?
Fracture risk often begins to decline after steroids are stopped, and bone density may stabilize or partly recover. The risk does not immediately become zero because prior fractures, age, ongoing illness, and falls still matter. Your clinician should reassess your risk over time.
Can I stop my osteoporosis medicine when my steroid dose reaches zero?
Do not stop osteoporosis medicine on your own after stopping steroids. A clinician may consider a planned break from a bisphosphonate, while denosumab requires a carefully planned transition to another treatment to reduce rebound bone loss and fracture risk.
How can I stay active if I am afraid of falling or breaking a bone?
Tell your care team if fear is limiting movement, exercise, social activities, or independence. Fall-proofing your home and working with a physical therapist on safe balance and functional-strength training can help you move with more confidence. Persistent pain after a vertebral fracture may also benefit from physical medicine or pain-management support.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.When should my next 'Bone Density and Vertebral Fracture Assessment' be scheduled to monitor my response to treatment?
  2. 2.If my blood tests for 'Bone Turnover Markers' show a change, does that mean my medication is working or that we need to adjust the dose?
  3. 3.Now that my steroid dose is being reduced, how does my long-term fracture risk change, and can we discuss an 'exit strategy' for my osteoporosis medication?
  4. 4.How do you distinguish between pain from my underlying condition and the persistent pain that might follow a spinal fracture?
  5. 5.Can you refer me to a physical therapist who specializes in 'safe movement' for people with vertebral fractures?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

    Laurent MR, Goemaere S, Verroken C, et al.

    Frontiers in endocrinology 2022; (13()):908727 doi:10.3389/fendo.2022.908727.

    PMID: 35757436
  2. 2

    2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

    Humphrey MB, Russell L, Danila MI, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(12)):2088-2102 doi:10.1002/art.42646.

    PMID: 37845798
  3. 3

    A review of the use of dual-energy X-ray absorptiometry (DXA) in rheumatology.

    Tanner SB, Moore CF

    Open access rheumatology : research and reviews 2012; (4()):99-107 doi:10.2147/OARRR.S29000.

    PMID: 27790018
  4. 4

    Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.

    Lorentzon M, Branco J, Brandi ML, et al.

    Advances in therapy 2019; (36(10)):2811-2824 doi:10.1007/s12325-019-01063-9.

    PMID: 31440982
  5. 5

    Use of bone turnover markers in postmenopausal osteoporosis.

    Eastell R, Szulc P

    The lancet. Diabetes & endocrinology 2017; (5(11)):908-923 doi:10.1016/S2213-8587(17)30184-5.

    PMID: 28689768
  6. 6

    Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

    Bhattoa HP, Vasikaran S, Trifonidi I, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025; (36(4)):579-608 doi:10.1007/s00198-025-07422-3.

    PMID: 40152990
  7. 7

    Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

    Szulc P, Naylor K, Hoyle NR, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2017; (28(9)):2541-2556 doi:10.1007/s00198-017-4082-4.

    PMID: 28631236
  8. 8

    The impact of frailty and fear of falling on health-related quality of life in older adults with osteoporosis: a cross-sectional study.

    Zhang L, Liu L, Chen C, et al.

    BMC geriatrics 2025; (25(1)):938 doi:10.1186/s12877-025-06625-x.

    PMID: 41272533
  9. 9

    Understanding Patients' Perspectives and Educational Needs by Type of Osteoporosis in Men and Women and People with Glucocorticosteroid-Induced Osteoporosis: A Qualitative Study to Improve Disease Management.

    Beauvais C, Poivret D, Lespessailles E, et al.

    Calcified tissue international 2019; (105(6)):589-608 doi:10.1007/s00223-019-00607-z.

    PMID: 31506706
  10. 10

    Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients.

    Adler RA

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2019; (22(1)):20-24 doi:10.1016/j.jocd.2018.03.004.

    PMID: 29941355
  11. 11

    Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.

    Amiche MA, Albaum JM, Tadrous M, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016; (27(5)):1709-18 doi:10.1007/s00198-015-3455-9.

    PMID: 26694595
  12. 12

    Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink.

    Abtahi S, Driessen JHM, Burden AM, et al.

    Rheumatology (Oxford, England) 2022; (61(4)):1448-1458 doi:10.1093/rheumatology/keab548.

    PMID: 34255815
  13. 13

    Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort.

    Bours S, de Vries F, van den Bergh JPW, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016; (27(4)):1603-1610 doi:10.1007/s00198-015-3426-1.

    PMID: 26630976
  14. 14

    Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients with Rheumatic Diseases Treated with Glucocorticoids.

    Nowakowska-Płaza A, Wroński J, Sudoł-Szopińska I, Głuszko P

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2021; (53(8)):499-503 doi:10.1055/a-1528-7261.

    PMID: 34384106
  15. 15

    Long-Term Bone Density Changes and Fracture Risk in Myasthenia Gravis: Implications for FRAX® Tool Application.

    Konno S, Uchi T, Kihara H, Sugimoto H

    Healthcare (Basel, Switzerland) 2024; (12(17)) doi:10.3390/healthcare12171793.

    PMID: 39273817
  16. 16

    Management of glucocorticoid-related osteoporotic vertebral fracture.

    Wong SPY, Mok CC

    Osteoporosis and sarcopenia 2020; (6(1)):1-7 doi:10.1016/j.afos.2020.02.002.

    PMID: 32226826
  17. 17

    Interventions to Prevent Falls in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guirguis-Blake JM, Perdue LA, Coppola EL, Bean SI

    JAMA 2024; (332(1)):58-69 doi:10.1001/jama.2024.4166.

    PMID: 38833257

This page explains long-term monitoring and self-care for glucocorticoid-induced osteoporosis for informational purposes only and does not replace medical advice. Ask your clinician before changing steroid or osteoporosis medicines, scan timing, or activity.

Get notified when new evidence is published on glucocorticoid-induced osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.